Evolution of Systemic Therapy in Metastatic Pancreatic Ductal Adenocarcinoma.
Pancreatic ductal adenocarcinoma is characterized by early systemic dissemination, a complex tumor microenvironment, as well as significant intratumoral and intertumoral heterogeneity. Treatment options and survival in pancreatic ductal adenocarcinoma have improved steadily over the last 3 decades. Although cytotoxic chemotherapy is currently the mainstay of treatment for pancreatic ductal adenocarcinoma, evolving therapeutic strategies are aimed at targeting the tumor microenvironment, metabolism, and the tumor-host immune balance.
['Kamgar|Mandana|M|', 'Chakrabarti|Sakti|S|', 'Shreenivas|Aditya|A|', 'George|Ben|B|']
D000230:Adenocarcinoma D000971:Antineoplastic Combined Chemotherapy Protocols D021441:Carcinoma, Pancreatic Ductal D006801:Humans D010190:Pancreatic Neoplasms D059016:Tumor Microenvironment
Evolution Chemotherapy Adenocarcinoma of the pancreas Pancreatic cancer Systemic treatment